Maravai LifeSciences' (MRVI) TriLink BioTechnologies said Monday it partnered with Avantor (AVTR) to expand the availability of its innovative nucleic acid products to customers across Europe, the Middle East, and Africa.
The company said the distribution partnership is expected to streamline the ordering process and shorten lead times for European customers.
Under the agreement, TriLink's key products, including CleanCap cap analogs, catalog mRNAs, over 150 modified and unmodified nucleotides, and high-performance IVT enzymes like CleanScribe RNA Polymerase, are more widely available in the region.
It added that TriLink's products will soon be available on Avantor's eCommerce platform, MarketSource.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。